REVOLUTION MEDICINES INC (1RVMD.MI) Forecast, Price Target & Analyst Ratings
BIT:1RVMD • US76155X1000
83 EUR
-17 (-17%)
Last: Jan 29, 2026, 07:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REVOLUTION MEDICINES INC (1RVMD.MI).
Forecast Snapshot
Consensus Price Target
€100.64
+ 21.25% Upside
Next Earnings Forecast
Release DateMar 2, 2026
PeriodQ4 / 2025
EPS Estimate-$1.62
Revenue Estimate3.972M
ChartMill Buy Consensus
87.41%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
€100.64
Upside
+ 21.25%
From current price of €83.00 to mean target of €100.64, Based on 27 analyst forecasts
Low
€64.12
Median
€92.70
High
€155.24
Price Target Revisions
1 Month
45.64%
3 Months
N/A
Price Target Summary
27 analysts have analysed 1RVMD.MI and the average price target is 100.64 EUR. This implies a price increase of 21.25% is expected in the next year compared to the current price of 83.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.41%
1RVMD.MI was analyzed by 27 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about 1RVMD.MI.
In the previous month the buy percentage consensus was at a similar level.
1RVMD.MI was analyzed by 27 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 2, 2026
PeriodQ4 / 2025
EPS Estimate-$1.62
Revenue Estimate3.972M
Revenue Q2QN/A
EPS Q2Q-44.29%
Number of Analysts21
Next Earnings Revisions
Revenue (1 Month)
34.87%
Revenue (3 Months)
N/A
EPS (1 Month)
1.50%
EPS (3 Months)
N/A
Next Earnings Summary
1RVMD.MI is expected to report earnings on 3/2/2026. The consensus EPS estimate for the next earnings is -1.62 EUR and the consensus revenue estimate is 3.97M EUR.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 29.39M -31.62% | 35.38M 20.38% | 11.58M -67.27% | 306K -100.00% | 4.22M | 35.885M 750.36% | 232.45M 547.76% | 735.28M 216.32% | 1.628B 121.41% | 2.984B 83.29% | 4.589B 53.79% | 6.024B 31.27% | 7.195B 19.44% | |
| EBITDA YoY % growth | -183.86M -71.80% | -253.24M -37.74% | -481.075M -89.97% | -673.512M -41.74% | -1.148B -68.30% | -1.399B -21.92% | -1.46B -4.35% | -802.633M 45.03% | -385.637M 51.95% | 957.93M 348.40% | 2.661B 177.79% | 3.557B 33.67% | 4.196B 17.96% | |
| EBIT YoY % growth | -188.01M -69.84% | -258.28M -37.38% | -487.185M -88.63% | -680.641M -41.53% | -1.158B -67.87% | -1.297B -12.06% | -1.159B 10.67% | -746.075M 35.61% | -26.614M 96.43% | 971.13M 3,748.94% | 2.162B 122.63% | 3.074B 42.18% | 3.805B 23.78% | |
| Operating Margin | -639.71% | -730.02% | -4,207.12% | -222,431.83% | -27,429.69% | -3,614.67% | -498.48% | -101.47% | -1.63% | 32.54% | 47.11% | 51.03% | 52.88% | |
| EPS YoY % growth | -2.56 -19.63% | -3.10 -21.09% | -3.77 -21.71% | -3.54 5.38% | -5.71 -59.94% | -6.76 -18.47% | -6.07 10.33% | -3.59 40.83% | -0.17 95.20% | 4.32 2,609.59% | 9.48 119.36% | 13.16 38.76% | 16.10 22.34% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.62 -44.29% | -1.69 -49.65% | -1.76 -34.09% | -1.79 -11.37% | -1.73 -6.90% | -1.58 6.51% | -1.51 14.06% | -1.44 19.79% | -1.36 21.47% |
| Revenue Q2Q % growth | 3.972M | 9.871M 148.51% | 20.4M | 40.8M | 61.2M | 73.114M 640.69% | |||
| EBITDA Q2Q % growth | -320.722M -53.69% | -341.936M -47.21% | -354.153M -42.28% | -363.179M -17.55% | -361.223M -12.63% | -327.614M 4.19% | -311.498M 12.04% | -298.768M 17.74% | -288.344M 20.18% |
| EBIT Q2Q % growth | -323.794M -49.69% | -336.18M -52.60% | -345.39M -44.14% | -352.316M -11.75% | -343.152M -5.98% | -328.858M 2.18% | -312.793M 9.44% | -296.82M 15.75% | -289.425M 15.66% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-19.33%
EPS Next 5 Year
14.31%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
812.44%
Revenue Next 5 Year
456.14%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-28.97%
EBIT Next 5 Year
7.47%
REVOLUTION MEDICINES INC / 1RVMD.MI Forecast FAQ
What is the price target for 1RVMD stock?
27 analysts have analysed 1RVMD.MI and the average price target is 100.64 EUR. This implies a price increase of 21.25% is expected in the next year compared to the current price of 83.
What is the next earnings date for 1RVMD stock?
REVOLUTION MEDICINES INC (1RVMD.MI) will report earnings on 2026-03-02, after the market close.
Can you provide the consensus estimates for REVOLUTION MEDICINES INC next earnings?
The consensus EPS estimate for the next earnings of REVOLUTION MEDICINES INC (1RVMD.MI) is -1.62 EUR and the consensus revenue estimate is 3.97M EUR.
How many analysts have analysed REVOLUTION MEDICINES INC (1RVMD.MI)?
The number of analysts covering REVOLUTION MEDICINES INC (1RVMD.MI) is 27.